Summary

Eligibility
for people ages up to 55 years (full criteria)
Location
at Los Angeles, California and other locations
Dates
study started
completion around

Description

Summary

Observational, noninterventional, 3-year study to examine the presence of detectable differences in neurocognitive, developmental, motor, neurophysiologic, and quality of life measures over time in patients with cyclin-dependent kinase-like 5 deficiency disorder.

Official Title

Endpoint Enabling Study of Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD)

Details

This is an observational study to examine the presence of detectable differences in neurocognitive, developmental, motor, neurophysiologic, and quality of life measures over time in approximately up to 100 patients aged birth to 55 years and diagnosed with cyclin-dependent kinase-like 5 deficiency disorder. Operational performance across age groups and languages will be assessed throughout the study, and Baseline cohort characteristics will be assessed throughout enrollment.

Keywords

Cyclin-Dependent Kinase-Like 5 Deficiency Disorder, CDKL5, CDD

Eligibility

You can join if…

Open to people ages up to 55 years

  1. Documented diagnosis of Cyclin-dependent Kinase-like 5 (CDKL5) deficiency disorder with pathogenic or likely pathogenic of CDKL5 variants
  2. Ages newborn to 55 years old
  3. Parent/Caregiver who is willing and capable of providing written informed consent
  4. Parent/caregiver lives with or has daily contact with study participant and able to provide consistent information across the study

You CAN'T join if...

  1. Any clinically significant neurocognitive deficit not attributable to Cyclin-dependent Kinase-like 5 (CDKL5) deficiency disorder or a secondary cause that may, in the opinion of the investigator, confound interpretation of study results (e.g., extreme prematurity, other genetic variants, unclassified CDKL5 variant, abnormal brain imaging, imaging and/or injury not otherwise attributable to CDD).
  2. Any condition that, in the opinion of the investigator, would put the patient at undue risk or make it unsafe for the patient to participate
  3. Any condition which would make the individual or the caregiver, in the opinion of the investigator, unsuitable for the study

Locations

  • UCLA Mattel Children's Hospital
    Los Angeles California 90095 United States
  • Children's Hospital Colorado
    Aurora Colorado 80045 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Loulou Foundation
ID
NCT05373719
Study Type
Observational
Participants
About 112 people participating
Last Updated